title: Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
abstract: Targeted therapies have changed the course of cancer treatment in recent years. By reducing toxicity and improving outcome, these new generations of precision medicines have extended patient lives beyond what could be achieved by the use of nontargeted therapies. In the last 2 years, several new molecular entities targeting signaling proteins and immune pathways have gone through successful clinical development resulting in their approval. These new targeted therapies require patient selection and the discovery of biomarkers of response. This review discusses the evolution of targeted therapies in cancer and challenges in translating the concepts into clinical practice.
authors.affiliation: MedGenome Inc., San Francisco, CA 94107, USA.
authors.forename: Sam
authors.initials: S
authors.lastname: Santhosh
authors.forename: Prasanna
authors.initials: P
authors.lastname: Kumar
authors.forename: Vedam
authors.initials: V
authors.lastname: Ramprasad
authors.forename: Amitabha
authors.initials: A
authors.lastname: Chaudhuri
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents
keywords: cancer; drug resistance; genetic alterations; targeted therapies